Ipsen receives approval from European Commission for Xermelo®

Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, announced that the European Commission(EC) has approved Xermelo® (telotristat ethyl) 250 mg three times a day (tid) for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analogue (SSA) therapy in adults inadequately controlled by SSA therapy.

• Source: Ipsen
• 492
• September 21, 2017